Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
Served areaEurope
HeadquartersVästra Trädgårdsgatan 15, 11153 Stockholm – Sweden
199,400,599
IPOJan. 1, 2000
Stock exchange(s)Nasdaq Stockholm